This is the authors' abstract. We don't add key points for this paper.
Biomarkers are emerging as potentially important diagnostic tools for cancer and many other diseases. However, many current detection systems for suffer from insufficient sensitivity. To address this concern, we developed a highly sensitive biosensor, featuring monoclonal antibody-coated polystyrene nanobeads assembled in the trenches of a microchip, for the detection of cancer biomarkers. These biosensors detected nucleosomes and carcinoembryonic antigen in serum at concentrations of 62.5 and 15.6 pg/mL, respectively. Very low detection limits that suggest such devices might be beneficial for the early detection of tumors and for monitoring of patients in remission.
No takes yet. Share an insight, caveat, or question.
Upponi et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: